Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

13

Revenue 2017

Bristol-Myers Squibb

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bristol-Myers Squibb's 2013 sales performance.

Bristol-Myers Squibb

CHMP backs Lynparza in breast cancer, Dupixent in asthma

CHMP backs Lynparza in breast cancer, Dupixent in asthma It was rejected by the CHMP a year ago. Ondexxya is intended for use in patients taking Pfizer/Bristol-Myers Squibb's Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) as

Reluctant shareholders threaten $74bn BMS merger with Celgene

Reluctant shareholders threaten $74bn BMS merger with Celgene Two prominent shareholders in Bristol-Myers Squibb have said they do not support the company’s $74bn mega-merger with Celgene and will try to stop the deal going through. ... attractive. “While Wellington agrees that Bristol-Myers should be active in

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma

FDA begins speedy review of Celgene’s Revlimid combo in lymphoma Nevertheless, the recent results came at a much-welcomed relief for both Celgene and Bristol Myers Squibb, which announced a $74 billion takeover of Celgene.

Fireworks likely at Senate drug pricing hearing today

Fireworks likely at Senate drug pricing hearing today 15:15 UK time, 16:15 in Europe) and will see the CEOs from AbbVie, AstraZeneca, Bristol-Myers Squibb, Merck &Co, Pfizer, and Sanofi (plus the head of J&J's

Innovent gears up for PD-1 inhibitor launch in China

Innovent gears up for PD-1 inhibitor launch in China The home-grown PD-1 inhibitors join Bristol-Myers Squibb and Merck &Co/MSD’s rival drugs on the Chinese market.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
JPA Health Communications

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics